(134 days)
No
The summary mentions "intelligent functions by image processing technologies" but does not explicitly mention AI, ML, or related terms like deep learning or neural networks. The description of performance studies focuses on standard software development processes and verification/validation, not on training or testing of AI/ML models.
No
This device is medical imaging software intended for reading, interpreting, and reporting various medical images. It provides tools for viewing, processing, and managing images to aid in diagnosis, not to perform therapy.
Yes
This device is medical imaging software intended to aid medical professionals in reading, interpreting, and reporting medical images to make a diagnosis, which falls under the definition of a diagnostic device.
Yes
The device description explicitly states "ASPIRE Bellus II is medical application software". The intended use and device description focus solely on software functionalities for viewing, processing, and reporting medical images. There is no mention of accompanying hardware components that are part of the device itself.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the software is for "reading, interpreting, reporting" medical images acquired from various imaging devices. It provides tools for viewing, processing, measuring, annotating, and managing these images. This is consistent with medical image viewing and processing software, not a device that performs tests on biological samples.
- Device Description: The description reinforces that it's medical application software for interpreting examination images and generating reports based on those images. It receives images via DICOM protocol.
- Lack of IVD Characteristics: There is no mention of analyzing biological samples (blood, urine, tissue, etc.), performing chemical or biological tests, or providing diagnostic information based on the results of such tests.
The software is a tool to aid medical professionals in interpreting images, which is a different function than an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
ASPIRE Bellus II is medical imaging software that is intended to provide trained medical imaging professionals, including Physicians and Radiologists, with tools to aid them in reading, interpreting, This product accepts DICOM compliant medical images acquired from a variety of imaging devices including, MG, CT, PT, MR, CR, DX, and US, etc. This product also provides general 2D/3D viewing and general image processing, measurements, annotations, reporting, printing, storing, and general image administration tools, etc.
This product does not accept lossy compressed mammographic images, which should not be used for primary diagnostic interpretation. Display monitors connected to this produt for diagnostic interpretation of mammographic images must be approved for use in digital mammography. All images sent to or imported into this product must conform to regulatory requirements. Image quality must conform to applicable quality guidelines.
Product codes
LLZ
Device Description
ASPIRE Bellus II is medical application software with speedy image display and intelligent functions by image processing technologies. This application can support user to efficiently perform interpretation of examination images and make a diagnosis using various modality images and generate Mammography reports for diagnostic/screening purposes. ASPIRE Bellus II can receive various diagnostic images directly from image acquisition systems or PACS via network using DICOM protocol. Images are displayed on viewer monitors for doctors' review.
Mentions image processing
Yes
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
MG, CT, PT, MR, CR, DX, and US, etc.
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
trained medical imaging professionals, including Physicians and Radiologists
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Nonclinical testing result:
The purpose of Software Development Process for ASPIRE Bellus II is to carry out the activities relating to the establishment of the software development plan (or plans) for definitely conducting software requirement analysis, architectural design, the detailed design, unit implementation and verification, software integration testing, software system test, software release, software maintenance. The main activities in software development process are described as follows.
- Software development plan ●
- Update of software development plan ●
- Software requirements analysis ●
- Software Architectural Design
- Software Detailed Design ●
- Software Unit Implementation and Verification .
- . Software Integration and Integration Testing
- Software System Testing .
- . Software Release
Clinical tests:
The subject of this 510(k) notification, ASPIRE Bellus II did not require clinical studies to support safety and effectiveness of the software.
Verification and Validation:
Software verification and validation have been performed by the following testing activities as defined in the procedure.
- . Unit test: Code verification has covered unit level verification activities and no independent unit testing was planned.
- Integration test: According to the procedure, no specific integration test was planned, but ● the test cases for integration were included in the initial part of system test including system software build process, which integrates all software modules, and testing using the build results.
- . System test: System test has been executed throughout the design verification phase and design validation phase.
Key results: Results of all conducted testing were acceptable in supporting the claim of substantial equivalence.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.2050 Medical image management and processing system.
(a)
Identification. A medical image management and processing system is a device that provides one or more capabilities relating to the review and digital processing of medical images for the purposes of interpretation by a trained practitioner of disease detection, diagnosis, or patient management. The software components may provide advanced or complex image processing functions for image manipulation, enhancement, or quantification that are intended for use in the interpretation and analysis of medical images. Advanced image manipulation functions may include image segmentation, multimodality image registration, or 3D visualization. Complex quantitative functions may include semi-automated measurements or time-series measurements.(b)
Classification. Class II (special controls; voluntary standards—Digital Imaging and Communications in Medicine (DICOM) Std., Joint Photographic Experts Group (JPEG) Std., Society of Motion Picture and Television Engineers (SMPTE) Test Pattern).
0
Image /page/0/Picture/2 description: The image shows the logo for the United States Department of Health and Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
FUJIFILM Medical Systems U.S.A., Inc. Jyh-Shyan Lin Senior Manager, Regulatory, Ouality and Clinical Affairs 419 West Avenue Stamford, Connecticut 06902
September 29, 2017
Re: K171463
Trade/Device Name: ASPIRE Bellus II Regulation Number: 21 CFR 892.2050 Regulation Name: Picture Archiving And Communications System Regulatory Class: Class II Product Code: LLZ Dated: August 25, 2017 Received: August 28, 2017
Dear Jyh-Shyan Lin:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device
1
related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education (DICE) at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely,
Michael D. O'Hara For
Robert A. Ochs, Ph.D Director Division of Radiological Health Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K171463
Device Name ASPIRE Bellus II
Indications for Use (Describe)
ASPIRE Bellus II is medical imaging software that is intended to provide trained medical imaging professionals, including Physicians and Radiologists, with tools to aid them in reading, interpreting, This product accepts DICOM compliant medical images acquired from a variety of imaging devices including, MG, CT, PT, MR, CR, DX, and US, etc. This product also provides general 2D/3D viewing and general image processing, measurements, annotations, reporting, printing, storing, and general image administration tools, etc.
This product does not accept lossy compressed mammographic images, which should not be used for primary diagnostic interpretation. Display monitors connected to this produt for diagnostic interpretation of mammographic images must be approved for use in digital mammography. All images sent to or imported into this product must conform to regulatory requirements. Image quality must conform to applicable quality guidelines.
| Type of Use (Select one or both, as applicable) | |
|---|---|
| ✖ Prescription Use (Part 21 CFR 801 Subpart D) | ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
| Date Prepared: | August 25, 2017 |
|---|---|
| Submitter's Information: | FUJIFILM Medical Systems U.S.A., Inc. |
| 419 West Avenue | |
| Stamford, Connecticut 06902 | |
| Telephone: (301) 251-1092 | |
| Fax: (203) 602-3785 | |
| Contact: Jyh-Shyan Lin | |
| Device Trade Name: | ASPIRE Bellus II |
| Device Common Names: | Picture Archiving and Communications System (PACS) |
| Device Clasification Name: | System, Image Processing, Radiological |
| Product Code: | LLZ |
| Regulation Number: | 21 CFR 892.2050 |
| Device Class: | Class II |
| Panel: | Radiology |
| Primary Predicate Device: | Synapse PACS 5.1.0 (K160108) |
| FUJIFILM Medical Systems U.S.A., Inc. | |
| Reference Predicate Device: | Senolris (K160937) |
| GE Healthcare |
4
1 . Description of the Device
ASPIRE Bellus II is medical application software with speedy image display and intelligent functions by image processing technologies. This application can support user to efficiently perform interpretation of examination images and make a diagnosis using various modality images and generate Mammography reports for diagnostic/screening purposes. ASPIRE Bellus II can receive various diagnostic images directly from image acquisition systems or PACS via network using DICOM protocol. Images are displayed on viewer monitors for doctors' review.
2. Indications for Use
ASPIRE Bellus II is medical imaging software that is intended to provide trained medical imaging professionals, including Physicians and Radiologists, with tools to aid them in reading, interpreting, reporting. This product accepts DICOM compliant medical images acquired from a variety of imaging devices including, MG, CT, PT, MR, CR, DX, and US, etc. This product also provides general 2D/3D viewing and general image processing, measurements, annotations, reporting, printing, storing, and general image administration tools, etc.
This product does not accept lossy compressed mammographic images, which should not be used for primary diagnostic interpretation. Display monitors connected to this product for diagnostic interpretation of mammographic images must be approved for use in digital mammography. All images sent to or imported into this product must conform to regulatory requirements. Image quality must conform to applicable quality guidelines.
3. Substantial Equivalence Comparison
ASPIRE Bellus II has the same intended use, similar labeling, and clinical application tools as those of the cleared primary predicate devices Synapse PACS 5.1.0 (K160108). The device features and technical characteristics comparison with predicates is shown as Table 1. Device Features and Technical Characteristics Comparison Matrix, and Table 2. Device Features and Technical Characteristics Comparison Matrix for displaying Mammography Tomosynthesis images.
| Device Parameters | ASPIRE Bellus II
(This submission) | Synapse PACS 5.1.0
(K160108)
(Primary predicate) |
|-------------------------------------------------------------------------------|--------------------------------------------------------------|---------------------------------------------------------|
| Product availability | Provided as Software only | Provided as Software only |
| Operating Systems | Windows 7 Professional SP1
(64bit)/Windows 8.1/Windows 10 | Windows
XP/Vista/Windows7/Windo
ws8.1 |
| Device Parameters | ASPIRE Bellus II
(This submission) | Synapse PACS 5.1.0
(K160108)
(Primary predicate) |
| Web Browser | Internet Explorer Version: 11 | Internet Explorer Version:
10 or 11 or Google Chrome |
| Database and file access
method | Web based (http(s)) | Web based (http(s)) |
| Display of Digital Mammography
Images | Yes | Yes |
| Process of Digital
Mammography (Non-Processed
or For Process) Images | Yes | Yes |
| On-demand access to database
and images | Yes | Yes |
| Viewing study lists | Yes | Yes |
| Decompression for compressed
images before display | Yes | Yes |
| Display images | Yes | Yes |
| Viewing report | Yes | Yes |
| Hanging Protocol | Yes | Yes |
| Spine labeling | Yes | Yes |
| Reference line display | Yes | Yes |
| Key images identification | Yes | Yes |
| Link multiple series | Yes | Yes |
| Measurement Tools | Yes | Yes |
| Annotation Tools | Yes | Yes |
| Standard Image Manipulation
Tools (Window width/level,
Zoom, Pan, etc.) | Yes | Yes |
| FCR IPSS for Fuji-CR-images | Yes | Yes |
| CT IPSS for CT images | Yes | Yes |
| Orthogonal and Oblique Multi
Planar Reconstruction (MPR) | Yes | Yes |
| Maximum, Average, and
Minimum Intensity Projection
(MIP, MPVR, MinIP) | Yes | Yes |
| Independent Window/Level of
upper and lower images in | Yes | Yes |
| Device Parameters | ASPIRE Bellus II
(This submission) | Synapse PACS 5.1.0
(K160108)
(Primary predicate) |
| Fusion Study | | |
| Save Window/Level Preferences | Yes | Yes |
| Multi-Modal Fusion to include
MR/PET/NM/and CT | Yes | Yes |
| Compare Current Study to
previous study in Fusion View | Yes | Yes |
| Compare Current Study to Prior
Study in Compare Mode | Yes | Yes |
| Image and Data Processing | Client side (Image Viewer) | Server side |
| Technology Platform (Client) | Platform Independent (Browser
based UI) | Platform Independent
(Browser based UI) |
| Technology Platform (Server) | Windows 7 Professional SP1
(64bit)/Windows 10 Pro (64bit) | Window server |
| System Security | Windows Authentication | Windows Authentication |
| Programming Language(s)
(Synapse Client) | C++, C#,
HTML, JavaScript | Javascript (TypeScript),
HTML5, CSS |
Table 1. Device Features and Technical Characteristics Comparison Matrix
5
6
Table 2. Device Features and Technical Characteristics Comparison Matrix for functions for displaying Mammography Tomosynthesis images
| Device Parameters | ASPIRE Bellus II
(This submission) | Senolris
(K160937)
(Reference predicate) |
|------------------------------------------------------------------------------------------|---------------------------------------|------------------------------------------------|
| Support Multi-vendor Digital
Breast Tomography | Yes | Yes |
| Drive multi-modality
workflow from the PACS
study list, including
tomosynthesis | Yes | Yes |
| The ability to include
tomosynthesis images in the
hanging protocol | Yes | Yes |
| The display of synthetized
2D image | Yes | Yes |
7
4. Safety Information
ASPIRE Bellus II introduces no new safety or efficacy issues other than those already indentified with the predicate device. The Risk Management and the results of the Hazard Analysis combined with the appropriate preventive measures taken indicate that the device is of moderate concern as per the May 11, 2005 issue of the "Guidance for the Content of Premarket Submission for Software Contained in Medical Devices." The ASPIRE Bellus II labeling contains instructions for use and necessary cautions, warnings and notes to provide the safe and effective use of the device.
5. Testing and Performance Information
Nonclinical testing result:
The purpose of Software Development Process for ASPIRE Bellus II is to carry out the activities relating to the establishment of the software development plan (or plans) for definitely conducting software requirement analysis, architectural design, the detailed design, unit implementation and verification, software integration testing, software system test, software release, software maintenance. The main activities in software development process are described as follows.
- Software development plan ●
- Update of software development plan ●
- Software requirements analysis ●
- Software Architectural Design
- Software Detailed Design ●
- Software Unit Implementation and Verification .
- . Software Integration and Integration Testing
- Software System Testing .
- . Software Release
Clinical tests:
The subject of this 510(k) notification, ASPIRE Bellus II did not require clinical studies to support safety and effectiveness of the software.
Verification and Validation:
Software verification and validation have been performed by the following testing activities as defined in the procedure.
- . Unit test: Code verification has covered unit level verification activities and no independent unit testing was planned.
8
- Integration test: According to the procedure, no specific integration test was planned, but ● the test cases for integration were included in the initial part of system test including system software build process, which integrates all software modules, and testing using the build results.
- . System test: System test has been executed throughout the design verification phase and design validation phase.
Cybersecurity:
The confidentiality, integrity and availability are maintained by ASPIRE Bellus II in accordance with Section 6 of the Content of Premarket Submissions for Management of Cybersecurity in Medical Devices; Guidance for Industry and Food and Drug Administration Staff (October 2, 2014).
ASPIRE Bellus II is connected through DICOM standard to medical devices such as CT, MR, CR, US, NM, PT, XA, etc. and to a PACS system storing data generated by these medical devices, and it retrieves image data via network communication based on the DICOM standard. Therefore ASPIRE Bellus II assure an adequate degree of protection for cybersecurity.
Performance standards:
- . Digital Imaging and Communications in Medicine (DICOM) Set (PS 3.1 - 3.18).
- Medical device software Software life cycle processes (IEC 62304 First edition 2006-05). .
- Medical devices Application of risk management to medical devices (14971 Second . Edition 2007-03-01).
6. Conclusion
Performance tests were conducted to test the functionality of the subject device, ASPIRE Bellus II. Results of all conducted testing were acceptable in supporting the claim of substantial equivalence.